摘要
耐多药结核病是全球结核病防治的主要问题,但国内外治疗成功率偏低,亟需研发新型抗结核病药物并优化抗结核治疗方案。德拉马尼是近年来上市的对耐多药结核病具有较好活性的药物,目前我国尚缺乏其治疗结核病的临床用药指导意见。为规范德拉马尼在临床中的合理应用,中华医学会结核病学分会组织相关领域专家制定了本共识,对其分子结构及抗结核机制、药效/药代动力学、耐药机制和临床研究分别进行了阐述,并对临床应用提出了推荐意见,对其适应人群、禁忌证、使用方法、不良事件和注意事项等分别说明,以期为临床医生使用德拉马尼提供参考。
Multidrug-resistant tuberculosis(MDR-TB)is a major problem in the prevention and treatment of tuberculosis worldwide,but the treatment success rate is low,and it is necessary to develop new anti-tuberculosis drugs and optimize treatment.Delamanid,a drug with good activity against MDR-TB,has been marketed in recent years.However,there is a lack of clinical medication guidance of delamanid for tuberculosis treatment.To standardize the rational application of delamanid in clinical practice,Chinese Tuberculosis Society organized experts in related fields to issue this consensus.This consensus described the molecular structure,anti-tuberculosis mechanism,pharmacodynamics/pharmacokinetics,drug resistance mechanism,and clinical research of delamanid,put forward recommendations for clinical application,and explained its suitable population,contraindications,methods of application,adverse events,and precautions,so as to provide a reference for clinicians to use delamanid.
作者
中华医学会结核病学分会
吴桂辉
高孟秋
Chinese Society of Tuberculosis,Chinese Medical Association;Wu Guihui;Gao Mengqiu(不详;Public Health Clinical Center of Chengdu,Chengdu 610061,China;Beijing Chest Hospital,Capital Medical University,Beijing 101149,China)
出处
《中华结核和呼吸杂志》
CAS
CSCD
北大核心
2022年第9期872-880,共9页
Chinese Journal of Tuberculosis and Respiratory Diseases
基金
北京市临床重点专科项目(20201214)
成都市科技局技术创新研发项目(2022⁃YF05⁃02139⁃SN)。
